Orthocell Gains Health Canada Approval for Nerve Repair Product Remplir

Orthocell Ltd ( (AU:OCC) ) just unveiled an announcement.

Orthocell Limited has received regulatory approval from Health Canada to sell its nerve repair product, Remplir™, in the Canadian market, which is valued at US$75 million. This approval expands the total addressable market for Remplir to US$1.8 billion, following recent approvals in the US and Thailand, and existing approvals in Australia, New Zealand, and Singapore. The company plans to appoint local distributors in Canada to drive sales, with first sales expected in the second half of 2025. Orthocell is well-funded with A$31.7 million in cash reserves, positioning it to capitalize on these new market opportunities and continue its global expansion strategy.

More about Orthocell Ltd

Orthocell Limited is a regenerative medicine company based in Perth, Australia. The company specializes in developing and commercializing collagen-based medical devices, with a focus on products that aid in nerve repair and regeneration. Orthocell’s flagship product, Remplir™, is a collagen wrap used in nerve repair surgeries.

YTD Price Performance: 2.94%

Average Trading Volume: 1,595,344

Technical Sentiment Signal: Sell

Current Market Cap: A$338.8M

See more insights into OCC stock on TipRanks’ Stock Analysis page.